Collaboration Agreement

Provexis PLC
12 September 2005


                                  PROVEXIS PLC
                          ('Provexis' or the 'Company')
                                        
             COLLABORATION AGREEMENT FOR CROHN'S DISEASE TECHNOLOGY

Exercise of right to assign intellectual property from University of Liverpool


Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, is delighted to announce that it has entered into
a collaboration agreement with a leading clinical nutrition company ('the
Company').

Provexis is currently developing a proprietary bioactive extract from the
Plantain (part of the banana family) which is designed to extend remission in
patients suffering from Inflammatory Bowel Disease (IBD). IBD has two forms,
Crohn's Disease and Ulcerative Colitis, both are chronic inflammatory diseases
of the digestive tract which, combined, affect approximately 1 in 400 in the
western world countries.

Under the terms of the collaboration agreement, Provexis and the Company will
develop a medical food product incorporating this bioactive extract. It is
intended that the food product will enter clinical trials in 2006 on patients
suffering from Crohn's disease. Crohn's Disease is currently incurable with the
primary goals of treatment being control of the inflammation, the relief of
symptoms, addressing nutritional deficiencies and the extension of remission
time.

The Company will be responsible for the formulation, manufacture and packaging
of the medical food product to be used in the full clinical trial and will have
the option of securing an exclusive negotiation period after the trial. The
negotiation period would give the Company the rights to be the first company to
pursue the manufacturing and distribution rights for the product. However,
Provexis is not obliged to enter into an agreement with the Company for these
rights and furthermore, all intellectual property, including the industrial
formulation of the medical food product, is wholly-owned by Provexis.

In addition, following successful pre-clinical studies on this medical food
treatment by the University of Liverpool and Provexis, Provexis has exercised
its right to the assignment of the intellectual property from the University of
Liverpool to a new Provexis subsidiary in which the University will be a
minority shareholder.

The specific components in Plantain with this therapeutic potential were
discovered by Professor Jon Rhodes, based in the Department of Medicine at the
University of Liverpool and an Honorary Consultant Gastroenterologist at the
Royal Liverpool University Hospital.

Dr Stephen Franklin, CEO of Provexis, commented: 'This is another significant
milestone in the development of Provexis. This collaboration is an important
validation of the strength of the Provexis technology pipeline.'


                                      Ends


For further information please contact:

Provexis plc
Dr Stephen Franklin, CEO                      07710 348 774

Bell Pottinger Corporate and Financial
Ann-Marie Wilkinson/Emma Kent                 020 7861 3232


Notes to Editors

Provexis develops scientifically proven functional and medical foods. Functional
foods are foods such as Benecol and Flora pro.activ that contain physiologically
active food components and provide health benefits beyond basic nutrition.
Medical foods are administered to patients by a physician for the dietary
management of specific diseases.

In June 2005 the Company joined AIM via a reverse takeover by Nutrinnovator.
Nutrinnovator brings with it a technology pipeline as well as marketing, selling
and business development skills.

Provexis was formed in December 1999 by the life-science subsidiary of the
venture-management company, ANGLE plc. In January 2000, Provexis entered into a
new technology option agreement with Rowett Research Services Ltd. (RRS), the
commercial subsidiary of the Aberdeen based Rowett Institute, and this option
was exercised in November 2001. Provexis' agreements with RRS have provided it
with the intellectual property rights pertaining to its lead product, Fruitflow.
Provexis continues to have strong links with the Rowett Institute, which
provides the company with R&D facilities, human trials and, potentially, new
technologies.


IBD - Technical

Researchers at the University of Liverpool have recognised that IBD may
represent an altered response to normal intestinal microbes In particular, they
believe there is a possibility that apparently non-pathogenic 'harmless '
bacteria can cause inflammation if they penetrate the intestinal mucus and
associate themselves with the lining cells of the intestine.

The researchers have characterised the adherence of Inflammatory Bowel Disease
related bacteria to carbohydrate structures on the lining of the intestine and
found that the adhesion of such bacteria to cell surfaces can be blocked by
some, but not all, complex carbohydrates. In particular, they found that
specific types of soluble fibre, extracted from Plantain, were particularly
effective for preventing bacterial adhesion and accordingly may have efficacy
for preventing or treating IBD. They believe that the soluble fibres may either
mimic or compete with bacterial receptors, thus preventing bacterial recruitment
and subsequent inflammation.

This discovery has led Provexis to believe that a Plantain--based formulation
(as developed by chemists at Provexis and tested at the University of Liverpool) 
could underpin a new medical food treatment for extending remission time in
patients with IBD.

The medical food product is anticipated to enter a two-site clinical trial on
patients with Crohn's Disease in Summer 2006.



                      This information is provided by RNS
            The company news service from the London Stock Exchange